Physician Knowledge and Awareness of CA-125 as a Screen for Ovarian Cancer in the Asymptomatic, Average-Risk Population

被引:4
|
作者
Stewart, Sherri L. [1 ]
Rim, Sun Hee [1 ]
Gelb, Cynthia A. [1 ]
机构
[1] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA
关键词
CA-125; ovarian cancer; screen; ELECTIVE OOPHORECTOMY; DIAGNOSTIC MARKERS; WOMEN; DISEASE; SERUM; HYSTERECTOMY; MAMMOGRAPHY; MENOPAUSE; BEHAVIOR; THERAPY;
D O I
10.1177/1090198111407185
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Effective early detection strategies for ovarian cancer do not exist. Current screening guidelines recommend against routine screening using CA-125 alone or in combination with transvaginal ultrasonography (TVS). In this study, the authors used the 2008 DocStyles survey to measure clinician beliefs about the effectiveness of CA-125 and TVS in the asymptomatic, average-risk population in the United States. To assess the need for provider education, the authors used the 2008 HealthStyles survey to examine public awareness of CA-125. Of 1,250 physician respondents, 40.4% said both CA-125 and TVS were effective screens, and 28.3% said neither was an effective ovarian cancer screen in the asymptomatic, average-risk population. Obstetrician/gynecologists [OB/GYNs] more often had responses consistent with current guidelines: 56.5% of OB/GYNs, compared with 34.4% and 29.8% of family/general practitioners and internists, respectively, said neither CA-125 nor TVS was an effective screen. Almost one third of women surveyed reported having heard of CA-125, and about one tenth said they had the CA-125 test. These findings support the need for additional provider education. Educational efforts should include lack of evidence for, as well as the potential harms of, screening for ovarian cancer with CA-125.
引用
收藏
页码:57 / 66
页数:10
相关论文
共 50 条
  • [31] CA-125 blood test in early detection of ovarian cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2015, 16 (06): : E269 - E269
  • [32] CA-125 RELIABILITY IN PREDICTING OVARIAN-CANCER RECURRENCE
    ZANABONI, F
    PRESTI, M
    SCARFONE, G
    BOLIS, G
    TUMORI, 1989, 75 (01) : 69 - 71
  • [33] The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review
    Momenimovahed, Zohre
    Mazidimoradi, Afrooz
    Allahqoli, Leila
    Salehiniya, Hamid
    CANCER REPORTS, 2025, 8 (03)
  • [34] CA-125 as response criterion in patients with epithelial ovarian cancer
    Zirpel, I
    Illiger, HJ
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (04) : 200 - 200
  • [35] Lights and shadows of the tumoral marker CA-125 in ovarian cancer
    Alfonso Sánchez Muñoz
    Antonio González Martín
    César Mendiola Fernández
    Clinical and Translational Oncology, 2008, 10
  • [36] Serum CA-125 screening for ovarian cancer in patients with dermatomyositis
    Whitmore, SE
    Anhalt, GJ
    Provost, TT
    Zacur, HA
    Hamper, UM
    Helzlsouer, KJ
    Rosenshein, NB
    GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 241 - 244
  • [37] Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
    Metzler, Julian Matthias
    Fink, Daniel
    Imesch, Patrick
    APPLIED SCIENCES-BASEL, 2021, 11 (01): : 1 - 6
  • [38] ELEVATION OF CA-125 PRIOR TO RECURRENCE OF OVARIAN-CANCER
    KNAPP, RC
    LAVIN, PT
    SCHAETZL, E
    NILOFF, JM
    BAST, RC
    GYNECOLOGIC ONCOLOGY, 1985, 20 (02) : 263 - 264
  • [39] CA-125 PROSPECTS IN EARLY DIAGNOSIS OF OVARIAN-CANCER
    EINHORN, N
    TUMOUR BIOLOGY, 1986, 7 (04): : 297 - 297
  • [40] Lights and shadows of the tumoral marker CA-125 in ovarian cancer
    Sanchez Munoz, Alfonso
    Gonzalez Martin, Antonio
    Mendiola Fernandez, Cesar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (08): : 449 - 452